

IN THE CLAIMS:

1. (Amended) A composition based on plant extracts, with an anti-oxidant activity which is particularly useful ~~in the prevention and treatment of circulation problems and in the prevention and treatment of adiposity~~, characterized for the treatment of adiposity and cellulitis in humans, wherein said composition comprises: in that its active ingredients ~~comprise, in association,~~
biflavones of *Ginkgo biloba*,
catechine and/or epicatechine,
cumarine or derivatives thereof,
iodine, and
a component chosen from among madecassic acid, asiatic acid, asiaticoside and mixtures of these.
2. (Amended) A composition according to Claim 1, ~~characterised in that it~~ wherein said composition is obtained by mixing plant extracts, ~~containing the aforesaid active principles.~~
3. (Amended) A composition according to Claim 2, ~~characterised in that the~~ wherein said extracts are in phytosomal form.
4. (Amended) A composition according to ~~any one of the preceding Claims,~~ claim 1 wherein said composition further includes flavonol glucosides and lactonic terpenes.
5. (Amended) A composition according to ~~any Claim from 1 to 4, characterised in that~~ it claim 1 wherein said composition also includes ~~an active principle~~ a compound chosen from the group consisting of methylxanthinic derivatives, chlorogenic acids, mono- and di-

caffeoylchinic acid and derivatives thereof, eicosapentaenoic acid, docohexaenoic acid, gamma-linolenic acid and mixtures thereof.

6. (Amended) A composition according to ~~any of Claims 1 to 4, characterised in that it~~
claim 1 wherein said composition is obtained by mixing plant extracts in the following percentages by weight:

1.5-32% of *Ginkgo biloba* biflavone extract;

6-80% of leucocyanidine;

1.5-32% of *Melilotus* and/or *Aesculus hyppocastanum* extract;

1.5-32% of centella extract;

1.5-85% extract of *Fucus vesiculosus*; ~~and optionally~~

~~1.5-32% of standardised *Ginkgo biloba* extract containing flavone glucosides and lactic terpenes.~~

7. (Amended) A composition according to Claim 6, ~~characterised in that with~~
~~reference to 100 parts of the basic mixture of Claim 6, it also includes one or more of the~~
~~following components~~ further comprising one or more of the following relative to 100 parts
of said composition:

from 1.5 to 32% by weight of *Ilex paraguariensis* extract;

from 1.5 to 32% by weight of artichoke extract;

from 5 to 80% by weight of fish oil; and

from 30 to 120% by weight of borage oil.

8. (Amended) A composition according to ~~any one of the preceding Claims~~ claim 1
which includes:

0.12-12%, ~~preferably 0.5-6%~~ by weight [[,]] of total biflavones;

0.2-12%, ~~preferably 0.5-8%~~ by weight [[,]] of catechine and/or epicatechine;

0.15-7%, ~~preferably 0.3-3.5%~~ by weight [[,]] of coumarin and derivatives thereof;

0.25-15%, ~~preferably 0.5-7.5%~~ by weight of asiaticoside;

0.25-22%, ~~preferably 0.5-11%~~ by weight ~~[[,]]~~ of asiatic acid and/or madecassic acid;
and

up to 0.5% of iodine, ~~and, optionally~~

~~0.25-12%, preferably 0.5-6% by weight, of flavonol glucosides and~~

~~0.1-2%, preferably 0.2-1% by weight, of lactonic terpenes.~~

9. (Amended) A composition according to Claim 8, ~~characterised in that it also~~
~~includes~~ further comprising one or more of the following components:

from 0.05 to 2.5%, ~~preferably 0.1-1%~~ by weight ~~[[,]]~~ of caffeine;

from 0.05 to 4.8%, ~~preferably 0.1-2.5%~~ by weight ~~[[,]]~~ of caffeilchinic acids;

from 0.75 to 24%, ~~preferably 1.5-12%~~ by weight ~~[[,]]~~ of eicosapentaenoic acid;

from 0.6 to 8%, ~~preferably 1.2-4%~~ by weight ~~[[,]]~~ of docoesaenoic acid; and

from 2.5 to 22%, ~~preferably from 5 to 11%~~ by weight of gamma-linolenic acid.

10. (Amended) A composition according to ~~any one of the preceding Claims~~ claim 1 in
a pharmaceutical form suitable for oral administration to a human.

11. (Cancelled)

12. (New) A composition according to claim 6 further comprising 1.5-32 wt% of
standardised *Ginkgo biloba* extract containing flavone glucosides and lactonic terpenes.

13. (New) A composition according to claim 8 which comprises:

0.5-6% by weight of total biflavones;

0.5-8% by weight of catechine and/or epicatechine;

0.3-3.5% by weight of coumarins and derivatives thereof;

0.5-7.5% by weight of asiaticoside; and

0.5-11% by weight of asiatic acid and/or madecassic acid.

14. (New) A composition according to claim 8 which further comprises:
0.25-12% by weight of flavonol glucosides and
0.1-2% by weight of lactonic terpenes.
15. (New) A composition according to claim 14 comprising:
0.5-6% by weight of flavonol glucosides, and
0.2-1% by weight, of lactonic terpenes.
16. (New) A composition according to claim 9 comprising:
0.1-1% by weight of caffeine;
0.1-2.5% by weight of caffeilchinic acids;
1.5-12% by weight of eicosapentaenoic acid;
1.2-4% by weight of docoesaenoic acid; and
5 to 11% by weight of gamma-linolenic acid.
17. (New) A method for treating adiposity and cellulites in a human with steps that
comprise administering to a human suffering from adiposity or cellulitis an effective amount
of a composition comprising a flavone dimer.
18. (New) A method according to claim 17 wherein said flavone dimer is a biflavone
extract of *Ginkgo biloba*.
19. (New) A method according to claim 18 wherein said biflavone extract comprises
amentoflavone, bilobetine, isoginkgetine, ginkgetine, or sciadopisitine.
20. (New) A method according to claim 19 wherein said composition further comprises
a flavonol glucoside or a lactonic terpene.